Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Synth supergroup

How Senti’s synthetic biology platforms could improve cell, gene therapies

February 27, 2018 12:33 PM UTC

With a $53 million series A announced on Tuesday, Senti Biosciences Inc. is combining synthetic biology platform technologies from more than five institutions to build an immunotherapy pipeline and a partnering engine. The company believes its engineered biological circuits will generate adaptive cell and gene therapies with controlled responses to environmental cues.

Synthetic biology circuits incorporate two or more artificial components into cells, typically encoded in DNA, to carry out novel functions. Senti is developing circuits to control when, where and how potently cell and gene therapies exert their effects in vivo...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article